✦ LIBER ✦

Evaluation of Self-Reported Progression and Correlation of Imatinib Dose to Survival in Patients with Metastatic Gastrointestinal Stromal Tumors: An Open Cohort Study

✍ Scribed by Jerry Call; Norman J. Scherzer; P. David Josephy; Christopher Walentas

Book ID: 107574708
Publisher: Springer US
Year: 2009
Tongue: English
Weight: 232 KB
Volume: 41
Category: Article
ISSN: 1941-6628
DOI: 10.1007/s12029-009-9111-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Correlation of immunophenotype with prog

Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate

✍ Lucian R. Chirieac; Jonathan C. Trent; Dejka M. Steinert; Haesun Choi; Ying Yang 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB

Expression of Bcl-2 in gastrointestinal

Expression of Bcl-2 in gastrointestinal stromal tumors : Correlation with progression-free survival in 81 patients treated with imatinib mesylate

✍ Dejka M. Steinert; Mauricio Oyarzo; Xuemei Wang; Haesun Choi; Peter F. Thall; L. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

## Abstract ## BACKGROUND The natural history of gastrointestinal stromal tumor (GIST) has been revolutionized by imatinib mesylate (imatinib) therapy. Before imatinib, Bcl‐2 expression in GIST was associated with a worse prognosis or added no additional prognostic value. To the authors' knowledge

Patterns of Care, Prognosis, and Surviva

Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib

✍ Antoine Italiano; Angela Cioffi; Paola Coco; Robert G. Maki; Patrick Schöffski; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 384 KB